PMA device
Visumax 800
Carl Zeiss Meditec, Inc. · Femtosecond Laser System For Refractive Correction (OTL, Class III) · First FDA decision Jan 10, 2024, newest Jan 10, 2024Nearsightedness and refractive error
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
PMA pathway
Device trials
2
Naming "Visumax 800"
MAUDE reports
0
Brand "Visumax 800", since 2015
PubMed studies
57
Mentioning "Visumax 800"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Visumax 800
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 0 of 1 decisions filed under this name.
FDA's records could not be loaded.
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "Visumax 800", any status and sponsor, newest update first.
- A Three-Phase Contralateral Comparison of Ray-Tracing Guided LASIK Versus Three Other Refractive Surgery Platforms to Correct Myopia or Myopia With AstigmatismPivotal-lookingRecruiting
Hoopes VisionAcademic, hospital or other
NCT07201298 · 120 participants (planned) · Start Sep 2025 · Primary completion Sep 2028
Device: Ray-Tracing Guided LASIK; Keratorefractive Lenticule Extraction (KLEx) and 2 more · For: Myopia; Astigmatism
Sites: Draper, Utah
Carl Zeiss Meditec AGNot on our public-company list
NCT04884672 · 237 participants · Start Jul 9, 2021 · Primary completion Mar 25, 2023
Device: SMILE · For: Myopia; Astigmatism
Sites: Aarhus, Denmark; Marburg, Germany; München, Germany · 5 sites in all
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Visumax 800", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code OTL
74 reports: 5 malfunction, 69 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
Z-0680-2020 · Started Dec 6, 2018
Reason given: VisuMax devices with software version 2.10.13 and activated SW-Module ReLEx (SMILE) option may experience a software issue. In case of a suction loss during treatment the software allows the user to choose the option immediate restart or restart treatment. Suction loss can occur in phase 1 through phase 5. The...
Cause as FDA categorized it: Software design · Device type: Femtosecond Laser System For Refractive Correction (OTL)
Published research
The most relevant PubMed records for "Visumax 800"[tiab]. The summary above synthesizes these.
- Comparison of Visual and Refractive Outcomes of Keratorefractive Lenticule Extraction for Compound Myopic Astigmatism Between VisuMax and VISUMAX 800.
Varman A, Varman A, Balakumar D · Clin Ophthalmol · 2024
- Refractive outcomes of small lenticule extraction (SMILE) Pro® with a 2 MHz femtosecond laser.
Saad A, Klabe K, Kirca M, et al. · Int Ophthalmol · 2024
- Refractive and Visual Outcomes of SMILE for Compound Myopic Astigmatism With the VISUMAX 800.
Reinstein DZ, Archer TJ, Potter JG, et al. · J Refract Surg · 2023
- The outcomes of first-generation (visumax 500) and second-generation (Visumax 800) keratorefractive lenticule extraction surgeries for astigmatism.
Lee CY, Lian LB, Chen HC, et al. · Sci Rep · 2024
- Comparison of Initial Visual Outcomes Following Keratorefractive Lenticule Extraction (KLEx) Using VisuMax 500 Versus VisuMax 800.
Davis JC, Sitto MM, Herrera E, et al. · Cureus · 2025
- Comparison of clinical outcomes following small incision lenticule extraction performed with the visumax 800 versus visumax 500 femtosecond laser.
Kim BK, Chung YT · Sci Rep · 2025Comparative Study
- The Efficiency, Predictability, and Safety of First-Generation (Visumax 500) and Second-Generation (Visumax 800) Keratorefractive Lenticule Extraction Surgeries: Real-World Experiences.
Lee CY, Lian IB, Chen HC, et al. · Life (Basel) · 2024
- Comparison of Intraoperative Time Taken for Docking, Lenticule Dissection, and Overall Workflow for SMILE Performed With the VisuMax 800 Versus the VisuMax 500 Femtosecond Laser.
Brar S, Ganesh S, Bhargav S · J Refract Surg · 2023Letter
- Comparison of early visual outcomes after SMILE using VISUMAX 800 and VISUMAX 500 for myopia: a retrospective matched case-control study.
Yoo TK, Kim D, Kim JS, et al. · Sci Rep · 2024Comparative Study
- Visual and Refractive Outcomes of Small Incision Lenticule Extraction With VisuMax 800 in 1,500 Eyes.
Ganesh S, Sriganesh SS, Karanam D · J Refract Surg · 2025
- Flap Optimization Using VISUMAX 800 Femtosecond Laser for Laser-Assisted In Situ Keratomileusis.
Virk A, Molleti S, Pawlowski H, et al. · J Clin Med · 2026
- Comparison of Refractive Outcomes Between Small Lenticule Extraction Using a 500 KHz and a 2 MHz Femtosecond Laser.
Kim JW, Eom Y, Kim DH, et al. · Diagnostics (Basel) · 2025
Other devices of this type
Also filed under product code OTL.
- VisuMaxCarl Zeiss Meditec, Inc. · PMA 2025
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.